ZA947823B - Polymer-bound camptothecin derivatives - Google Patents

Polymer-bound camptothecin derivatives

Info

Publication number
ZA947823B
ZA947823B ZA947823A ZA947823A ZA947823B ZA 947823 B ZA947823 B ZA 947823B ZA 947823 A ZA947823 A ZA 947823A ZA 947823 A ZA947823 A ZA 947823A ZA 947823 B ZA947823 B ZA 947823B
Authority
ZA
South Africa
Prior art keywords
pct
formula
camptothecin
units represented
hydroxy
Prior art date
Application number
ZA947823A
Other languages
English (en)
Inventor
Francesco Angelucci
Antonino Suarato
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of ZA947823B publication Critical patent/ZA947823B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA947823A 1993-10-08 1994-10-06 Polymer-bound camptothecin derivatives ZA947823B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives

Publications (1)

Publication Number Publication Date
ZA947823B true ZA947823B (en) 1995-07-03

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA947823A ZA947823B (en) 1993-10-08 1994-10-06 Polymer-bound camptothecin derivatives

Country Status (24)

Country Link
US (1) US5773522A (fr)
EP (1) EP0673258B1 (fr)
JP (1) JPH08504217A (fr)
KR (1) KR100359005B1 (fr)
CN (1) CN1138565C (fr)
AT (1) ATE239507T1 (fr)
AU (1) AU679788B2 (fr)
CA (1) CA2150132A1 (fr)
DE (1) DE69432627T2 (fr)
DK (1) DK0673258T3 (fr)
ES (1) ES2198421T3 (fr)
FI (1) FI952746A0 (fr)
GB (1) GB9320781D0 (fr)
HU (1) HU215588B (fr)
IL (1) IL111173A (fr)
MY (1) MY116624A (fr)
NZ (1) NZ273952A (fr)
PL (1) PL178132B1 (fr)
PT (1) PT673258E (fr)
RU (1) RU2149646C1 (fr)
TW (1) TW316905B (fr)
UA (1) UA42706C2 (fr)
WO (1) WO1995010304A1 (fr)
ZA (1) ZA947823B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE210673T1 (de) * 1996-09-30 2001-12-15 Bayer Ag Glycokonjugate von modifizierten camptothecin- derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (fr) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Derives polymeres de camptothecine amino-substitues et utilisation de ceux-ci pour la fabrication d'un medicament
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
CA2828605C (fr) 2010-05-25 2019-01-15 Syndevrx, Inc. Inhibiteurs des metap2 conjugues a des polymeres et leurs methodes d'utilisation dans le domaine therapeutique
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
BR112015025892A2 (pt) * 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
WO2015029615A1 (fr) * 2013-08-26 2015-03-05 独立行政法人科学技術振興機構 Adhésif
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3008960A1 (fr) 2016-01-11 2017-07-20 Syndevrx, Inc. Traitement de tumeurs induites par un dysfonctionnement metabolique
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
MY116624A (en) 2004-03-31
CN1138565C (zh) 2004-02-18
WO1995010304A1 (fr) 1995-04-20
NZ273952A (en) 1996-10-28
DE69432627D1 (en) 2003-06-12
EP0673258B1 (fr) 2003-05-07
KR100359005B1 (ko) 2003-04-26
CN1115564A (zh) 1996-01-24
PL178132B1 (pl) 2000-03-31
IL111173A (en) 1998-10-30
DE69432627T2 (de) 2004-03-25
UA42706C2 (uk) 2001-11-15
RU95112841A (ru) 1997-06-27
HU9502084D0 (en) 1995-09-28
PT673258E (pt) 2003-09-30
JPH08504217A (ja) 1996-05-07
IL111173A0 (en) 1994-12-29
RU2149646C1 (ru) 2000-05-27
AU679788B2 (en) 1997-07-10
HU215588B (hu) 1999-01-28
US5773522A (en) 1998-06-30
HUT71678A (en) 1996-01-29
DK0673258T3 (da) 2003-08-25
EP0673258A1 (fr) 1995-09-27
PL309328A1 (en) 1995-10-02
ES2198421T3 (es) 2004-02-01
TW316905B (fr) 1997-10-01
CA2150132A1 (fr) 1995-04-20
FI952746A (fi) 1995-06-05
GB9320781D0 (en) 1993-12-01
ATE239507T1 (de) 2003-05-15
FI952746A0 (fi) 1995-06-05
AU7783694A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
GB9320781D0 (en) Polymer-bound camptothecin derivatives
MX9408969A (es) Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas.
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
EP0694558A4 (fr) Nouveau sphingoglycolipide et son utilisation
MY109669A (en) N,o-sulphated heparosans, process for, preparing them and pharmaceutical compositions containing them
BG103673A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a
GR3031195T3 (en) A process for the preparation of anthracycline antibiotics
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
TW268015B (fr)
TW259787B (fr)
TW327170B (en) Aza-anthracyclinone derivatives
HUP9802072A2 (hu) Benzo-tiopiráno-indazol-származékok és az ezeket tartalmazó gyógyszerkészítmények
CA2037092A1 (fr) Derives insatures d'acides biliaires, procedes de preparation et compositions pharmaceutiques en contenant
DE3111859A1 (de) Di-n(pfeil hoch)6(pfeil hoch)(pfeil hoch)'(pfeil hoch),o(pfeil hoch)3(pfeil hoch)-desmethylistamycin a und verfahren zur herstellung desselben
ES456625A1 (es) Un procedimiento para preparar compuestos de acidos 3-cefem-4-carboxilicos 3,7-sustituidos.